Prelude Therapeutics Stock

preludetx.comHealthcareFounded: 2016Funding to Date: $95MM

Prelude Therapeutics is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet need.

Register for Details

For more details on financing and valuation for Prelude Therapeutics, register or login.

Please provide your first name.
Please provide your last name.
Please provide a valid email address.

By registering, you agree to the Forge Terms of Use. Already registered? Click here to log in

Enterprise Value (based on primary financings)

Enterprise Value

View Enterprise Value for Prelude Therapeutics.

Register Today

Team

Management Team

Krishna Vaddi Ph.D
Founder, Chief Executive Officer & Board Member
David Mauro Ph.D
Chief Medical Officer
Peggy Scherle Ph.D
Chief Scientific Officer

Board Members

Krishna Vaddi Ph.D
Paul Friedman
Kelvin Neu
David Bonita

Other companies like Prelude Therapeutics in the Healthcare sector

Sector
Last Round Est. Valuation
$3.6B
Sector
Last Round Est. Valuation
$2.15B
Sector
Last Round Est. Valuation
$334.19MM
Sector
Last Round Est. Valuation
$150MM
Sector
Last Round Est. Valuation
$4.8B
Sector
Last Round Est. Valuation
$1.08B
Sector
Last Round Est. Valuation
$296.3MM

News

Wilmington, Delaware-based clinical-stage biopharmaceutical company Prelude Therapeutics has raised $60 million in funding